copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
About BARDA (Biomedical Advanced Research and Development Authority) Dr Disbrow joined BARDA in January of 2007 and has held a variety of positions related to the advanced development and procurement of medical countermeasures against an array of threats to national security and public health
BARDA Newsroom - Medical Countermeasures The U S Department of Health and Human Services (HHS) announced on August 5, 2025, the beginning of a coordinated wind-down of mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA)
Medical Countermeasures | USA Public Health Security CMA provides flexible and innovative acquisition solutions in support of BARDA’s mission CMA strives to enhance the U S government’s contracting capabilities to respond quickly to both known and emerging public health threats
BARDA RESPONDS - Medical Countermeasures Since its inception, BARDA has been called on to respond to many health security threats, including the H1N1 influenza virus; Zika virus; Ebola, Sudan, and Marburg viruses; and SARS-CoV-2 BARDA has also been poised to respond to outbreaks caused by H5N1 and H7N9 influenza viruses
BARDA RESEARCH - Medical Countermeasures This manuscript describes key actions and strategies BARDA implemented with our existing partners to advance preparedness and enable rapid response to the 2022 and 2023 SUDV and MARV outbreaks in Africa in the absence of licensed vaccines
BARDA CBRN ANTIBACTERIAL MEDICAL COUNTERMEASURES PROGRAM BARDA is now seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections following a public health emergency
BARDA Division of Nonclinical Development (DNCD) DNCD provides BARDA and MCM developers the expertise and laboratory capacity to establish and share nonclinical models, conduct appropriate nonclinical studies to support U S Food and Drug Administration (FDA) approval, and evaluate potential MCM candidates prior to BARDA investment
BARDA INFLUENZA EMERGING INFECTIOUS DISEASES In alignment with the National Biodefense Strategy, BARDA is responsible for the advanced research and development (AR D), manufacturing, and procurement of medical countermeasures (MCMs) to protect the health security of the US public
FDA APPROVALS, LICENSURES CLEARANCES FOR BARDA SUPPORTED PRODUCTS FDA APPROVALS, LICENSURES CLEARANCES FOR BARDA SUPPORTED PRODUCTS BARDA supports a diverse portfolio of medical countermeasures and these products have received a total of 108 FDA approvals, licensures, or clearances